THE PHARMAGELLAN GUIDE TO INTERPRETING CLINICAL TRIAL RESULTS is a complete and concise reference to help you make sense of drug and device trials. Intended for non-statisticians, it’s chock-full of “news you can use" as your read companies’ press releases, abstracts, investor presentations, and publications, plus more detailed references if you want to dig deeper into methodology issues.
This new book will be published in Q1-2020 — but sign up today to receive regular updates, plus a pre-order discount offer later this year!
THE PHARMAGELLAN GUIDE TO BIOTECH FORECASTING AND VALUATION is your one-stop reference to make investment decisions, pitch to potential partners, or estimate the value of an R&D program.
- Bruce Booth, Partner, Atlas Venture
Learn how to get a free sample chapter on “Projecting Market Share for R&D-Stage Biotechs” here
Many early-stage drug development projects don't progress if the team is stretched thin, and people and resources are focused on more advanced assets.
To fully realize the value of projects under development, these companies need external support that is both senior-level and hands-on.
Pharmagellan offers just that: expert advice and project execution to biotech and pharma companies willing to discover how far they can go. Learn more about what we do and how we can help.
Preclinical, translational, and early clinical strategy and execution
Competitive and financial analysis of products, portfolios, and companies